NCT03204474View on ClinicalTrials.gov

A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 8, 2017

Primary Completion Date

July 28, 2017

Study Completion Date

July 28, 2017

Conditions
Healthy Male Chinese Volunteers
Interventions
DRUG

Lacosamide (LCM) tablet

Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg

DRUG

Lacosamide (LCM) solution for infusion

Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion

Trial Locations (1)

Unknown

Sp1043 001, Shanghai

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT03204474 - A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects | Biotech Hunter | Biotech Hunter